The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis

Rupesh Agrawal, Dinesh Visva Gunasekeran, Aniruddha Agarwal, Ester Carreño, Kanika Aggarwal, Bhaskar Gupta, Dhananjay Raje, Somasheila I. Murthy, Mark Westcott, Soon Phaik Chee, Peter McCluskey, Ho Su Ling, Stephen Teoh, Luca Cimino, Jyotirmay Biswas, Shishir Narain, Manisha Agarwal, Padmamalini Mahendradas, Moncef Khairallah, Nicholas JonesIlknur Tugal-Tutkun, Kalpana Babu, Soumayava Basu, Richard Lee, Hassan Al-Dhibi, Bahram Bodaghi, Alessandro Invernizzi, Debra A. Goldstein, Carl P. Herbort, Talin Barisani-Asenbauer, Julio J. González-López, Sofia Androudi, Reema Bansal, Bruttendu Moharana, Sarakshi Mahajan, Simona Esposti, Anastasia Tasiopoulou, Sengal Nadarajah, Mamta Agarwal, Sharanya Abraham, Ruchi Vala, Joanne Lord, Ramandeep Singh, Aman Sharma, Kusum Sharma, Manfred Zierhut, Onn Min Kon, John Kempen, Emmett T. Cunningham, Andres Rousselot, Quan Dong Nguyen, Carlos Pavesio, Vishali Gupta*

*Corresponding author for this work

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Purpose: To contribute a global description of the spectrum of choroidal involvement in tubercular uveitis (TBU). Methods: Retrospective cohort study of TBU patients with choroidal involvement from 25 centers between January 2004 and December 2014. Medical records of patients with a minimum follow-up of 1 year were reviewed. Results: 245 patients were included. The phenotypic variations included serpiginous-like choroiditis (SLC) (46%), tuberculoma (13.5%), multifocal choroiditis (MFC) (9.4%), ampiginous choroiditis (9%), among others. 219 patients were treated with anti-tubercular therapy (ATT) (n = 219/245, 89.38%), 229 patients with steroids (n = 229/245, 93.47%) and 28 patients with immunosuppressive agents (n = 28/245, 11.42%). Treatment failure was noted in 38 patients (n = 38/245, 15.5%). Patients with SLC and ampiginous choroiditis appeared to have superior outcomes on survival analysis (p = 0.06). Conclusion: This study provides a comprehensive description of choroidal involvement in TBU. Patients with SLC and ampiginous choroiditis may have better clinical outcomes.

Original languageEnglish (US)
JournalOcular Immunology and Inflammation
DOIs
StateAccepted/In press - 2018

Keywords

  • Anti-tubercular therapy
  • choroiditis
  • ocular
  • tuberculosis
  • uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint Dive into the research topics of 'The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis'. Together they form a unique fingerprint.

Cite this